Coegin Pharma AB (NGM:COEGIN)
Sweden · Delayed Price · Currency is SEK 3.010
-0.070 (-2.27%)
At close: Sep 29, 2026
Coegin Pharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.43 | 0.08 | - | - | - | - | |
Revenue Growth | - | - | - | - | - | - |
Cost of Revenue | 1.21 | 0.85 | 0.02 | 0.02 | - | - |
Gross Profit | -0.77 | -0.77 | -0.02 | -0.02 | - | - |
Selling, General & Admin | 18.23 | 16.9 | 20.29 | 25.21 | 34.94 | 31.91 |
Other Operating Expenses | -0.39 | -0.24 | 0.01 | -0.43 | -2.97 | -4.74 |
Operating Expenses | 20.84 | 19.68 | 23.32 | 27.8 | 34.69 | 27.18 |
Operating Income | -21.61 | -20.45 | -23.33 | -27.82 | -34.69 | -27.18 |
Interest Expense | -0.07 | -0.01 | -0.46 | -0.05 | -0.22 | - |
Interest & Investment Income | 0 | 0 | 0 | 0.02 | 0.01 | - |
Earnings From Equity Investments | - | - | -0.05 | - | - | - |
Currency Exchange Gain (Loss) | -0.02 | -0.02 | 0.06 | -0.14 | -0.33 | 0.04 |
Other Non Operating Income (Expenses) | 0 | 0 | - | - | - | - |
Pretax Income | -21.69 | -20.48 | -23.78 | -27.98 | -35.24 | -27.15 |
Income Tax Expense | 0.02 | 0.02 | - | - | - | - |
Net Income | -21.71 | -20.5 | -23.78 | -27.98 | -35.24 | -27.15 |
Net Income to Common | -21.71 | -20.5 | -23.78 | -27.98 | -35.24 | -27.15 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 26 | 25 | 19 | 9 | 7 | 6 |
Shares Outstanding (Diluted) | 26 | 25 | 19 | 9 | 7 | 6 |
Shares Change | 9.46% | 31.30% | 105.53% | 34.42% | 15.36% | 354.98% |
EPS (Basic) | -0.84 | -0.82 | -1.26 | -3.04 | -5.14 | -4.59 |
EPS (Diluted) | -0.87 | -0.82 | -1.26 | -3.04 | -5.14 | -4.59 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -21.8 | -16.67 | -23.64 | -22.03 | -38.23 | -21.49 |
Free Cash Flow Per Share | -0.84 | -0.67 | -1.25 | -2.39 | -5.58 | -3.61 |
Operating Margin | -4990.53% | -25889.87% | - | - | - | - |
Profit Margin | -5012.70% | -25945.57% | - | - | - | - |
Free Cash Flow Margin | -5035.34% | -21101.27% | - | - | - | - |
EBITDA | -18.61 | -17.42 | -20.32 | -24.79 | -31.97 | -27.17 |
D&A For EBITDA | 3 | 3.03 | 3.02 | 3.02 | 2.72 | 0.01 |
EBIT | -21.61 | -20.45 | -23.33 | -27.82 | -34.69 | -27.18 |
Revenue as Reported | 0.93 | 0.37 | 0.06 | 0.57 | 3.13 | 4.76 |